CAR-T cell therapy for relapsed or refractory B-cell blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are made from a donor to attack cancer cells in people with B-cell blood cancers that have come back or not responded to standard treatments. The goal is to see if these cells can help people who haven't had success with other therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a B-cell blood cancer like certain types of leukemia or lymphoma that has returned or not responded to treatment.
- You are between 18 and 70 years old.
- Your blood counts and organ function (kidney, liver, heart, lungs) are adequate as checked by tests.
- You have not had chemotherapy, radiation, or other cancer treatments in the last 2 weeks, and you have recovered from any side effects.
- You are willing to use effective birth control if you or your partner could become pregnant.
- You do not have uncontrolled infections, active hepatitis or HIV, or certain heart or brain conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial uses a patient's own T cells, modified to target a protein called CD19 on cancer cells, to treat B-cell cancers that have come back or not responded to standard treatments. It is for people aged 14 to 70 with certain types of leukemia or lymphoma.
This trial tests a new CAR-T cell therapy (called ssCART-19) for people with B-cell lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells to target and kill cancer cells.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This trial tests a personalized CAR-T cell treatment that targets a marker called CD79b in people whose B-blood cancers have come back or not responded to prior treatment. It may help your immune system find and attack cancer cells, but it also requires you to meet safety and health criteria.
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.